About Haematologic Technologies
Haematologic Technologies is a company based in Essex (United States) founded in 1987 was acquired by Edgewater Capital in October 2019. Haematologic Technologies operates in a competitive market with competitors including PrognomiQ, PreOmics, Vivostat, LenioBio and Expedeon, among others.
- Headquarter Essex, United States
- SectorsHealthcare
- Email••••••••
- Website haemtech.com
- Social LinkedIn X Facebook
- Acquired by Edgewater Capital (Oct 2019)
- Latest Funding Round$154.14K (USD), Grant
Jul 2018
- InvestorsNIH
& 2 more
- Acquired byEdgewater Capital
(Oct 2019)
Funding Insights of Haematologic Technologies
- Total Rounds 4
- Last Round Grant — $154,143
- First Round $350,951
(Aug 2004)
- Investors Count 2
All 4 funding rounds of Haematologic Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Haematologic Technologies
Haematologic Technologies has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and Edgewater Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
A private equity firm focused on performance materials is operated. | – | edgewatercapital.com | Cleveland, United States |
Investor details for Haematologic Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Haematologic Technologies
4 dated milestones of Haematologic Technologies across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Haematologic Technologies is founded.
- Funding First funding round of $351K.
- Funding Latest funding round, Grant, of $154K.
- Exit Acquired by Edgewater Capital.
Competitors of Haematologic Technologies
Haematologic Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PrognomiQ, PreOmics, Vivostat, LenioBio and Expedeon, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prognomiq.com | 2020 | San Mateo, United States | $90.36M | 24 | Developer of tests for the detection and treatment of cancer and other diseases | |
| preomics.com | 2014 | Munich, Germany | $19.14M | 22 | Reagents and instruments for proteomics research are supplied by PreOmics. | |
| vivostat.com | 2001 | Alleroed, Denmark | $12.89M | 9 | On-site fibrin sealant preparation systems are developed and provided. | |
| leniobio.com | 2016 | Dusseldorf, Germany | $13.01M | 18 | Kits for cell-free eukaryotic protein expression are provided. | |
| expedeon.com | 2003 | Swavesey, United Kingdom | $390,000 | 1,587 | Reagents and kits for protein-based research are developed and supplied. | |
| listlabs.com | 1978 | Campbell, United States | $48.4M | – | Specializes in the production of research reagents | |
| mjbiopharm.com | 2002 | Mumbai, India | $9.13M | 265 | Animal and human rDNA Insulin products and dosage forms | |
| acrobiosystems.com | 2016 | Newark, United States | – | 22 | Recombinant proteins are manufactured to support cancer immunotherapy efforts. | |
| anshlabs.com | 2010 | Webster, United States | – | 33 | Immunoassay reagents and kits are developed for life science research. |
Detailed competitors of Haematologic Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Haematologic Technologies
Websites that share an audience with Haematologic Technologies (haemtech.com).
Websites whose visitors overlap most with Haematologic Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| southernbiotech.com | 100% | – | #1,646,016 | View details | |
| neuromics.com | 100% | 25.3K | #1,118,534 | View details | |
| ptglab.com | 100% | – | #137,673 | View details | |
| complementtech.com | 99% | – | #3,741,875 | View details | |
| mpbio.com | 81% | 112.2K | #351,727 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Haematologic Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Haematologic Technologies
Complete news archive for Haematologic Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Haematologic Technologies
10 companies that operate in the same segment as Haematologic Technologies (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Haematologic Technologies
Haematologic Technologies was founded in 1987 and raised its 1st funding round 17 years after it was founded.
Haematologic Technologies is headquartered in Essex, United States.
Haematologic Technologies is engaged in manufacturing and marketing of plasma proteins and research reagents for in vitro research use. The company offers a wide range of proteins involved in the coagulation cascade, as well as the regulation of bone metabolism. Its product line includes purified plasma zymogens, enzymes, cofactors, inhibitors, substrates, antibodies, sample collection tubes and ELISA reagents. In addition, the company offers other services, which includes: custom protein purification, protein modification, assay development, contract manufacturing and contract research.
Haematologic Technologies has 3 investors. Key investors include NIH, HHS, and Edgewater Capital Partners.
Yes. Haematologic Technologies was acquired by Edgewater Capital in October 2019.